12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Corus CAD regulatory update

CardioDx said data from a health economics study showed its Corus CAD gene expression test as a first-line test prior to invasive or non-invasive imaging is cost-effective for assessing non-diabetic patients presenting with symptoms suggestive of coronary artery disease (CAD)....

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >